Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 04-2013 | 03-2013 | 01-2013 | 12-2012 | 10-2012 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 30 | N/A | N/A | 20 | 26 |
| Receivables | 32 | 0 | N/A | 7 | 7 |
| Other current assets | 0 | 0 | 0 | 3 | 5 |
| TOTAL | $65 | $N/A | $N/A | $30 | $38 |
| Non-Current Assets | |||||
| PPE Net | 70 | N/A | N/A | N/A | N/A |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 5 |
| TOTAL | $70 | $N/A | $N/A | $N/A | $5 |
| Total Assets | $134 | $N/A | $N/A | $40 | $43 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 10 | 0 | 0 | 4 | 4 |
| Accrued Expenses | 1 | 0 | N/A | 0 | N/A |
| TOTAL | $53 | $N/A | $N/A | $4 | $4 |
| Non-Current Liabilities | |||||
| Long Term Debt | 16 | 0 | N/A | 0 | N/A |
| TOTAL | $16 | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $69 | $N/A | $N/A | $4 | $4 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 13 | N/A | N/A | N/A | N/A |
| Common Shares | 3 | N/A | N/A | 3 | 3 |
| Retained earnings | 3 | N/A | N/A | 1 | 1 |
| Other shareholders' equity | 0 | 0 | 0 | -3 | 0 |
| TOTAL | $66 | $N/A | $N/A | $30 | $39 |
| Total Liabilities And Equity | $134 | $0 | $0 | $34 | $43 |